YD Bio (YDES) Total Non-Current Liabilities (2024 - 2025)
YD Bio (YDES) posted quarterly Total Non-Current Liabilities of -$14991.5 billion for Q4 2025, down 397264.27% year-over-year from N/an in Q4 2024, and down 397264.27% quarter-over-quarter from -$3.8 billion in Q4 2024.
YD Bio (YDES) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Total Non-Current Liabilities for 2 consecutive years, with -$14991.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 397264.27% year-over-year to -$14991.5 billion; the TTM figure through Dec 2025 stood at -$14991.5 billion (down 397264.27% YoY), while the FY2025 annual figure was -$14991.5 billion, down 397264.27% from the prior year.
- Total Non-Current Liabilities eased to -$14991.5 billion in Q4 2025 per YDES's latest filing, from -$3.8 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at -$3.8 billion in Q4 2024 and bottomed at -$14991.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | YD Bio | 314.91 Mn | 308.91 Mn | - | -14,991.47 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14,991.47 Bn |
| Dec 31, 2024 | -3.77 Bn |